Wednesday, May 9, 2018

Growing Adoption of Open Innovation Models in Pharmaceutical and Biotechnology Companies

Dublin, May 09, 2018 (GLOBE NEWSWIRE) — The “High Throughput Screening Market by Technology, Application, Product, End User – Global Forecast to 2023” report has been added to ResearchAndMarkets.com’s offering.

The global high-throughput screening (HTS) market is projected to reach USD 21.69 Billion by 2023 from USD 14.87 Billion in 2018, at a CAGR of 7.8%.

The major factors driving the growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments.

The report analyzes the global HTS market by product & service, technology, application, end user, and region. On the basis of product & service, the reagents & assay kits segment accounted for the largest share of the global HTS market in 2017. Factors such as the large numbers of reagents and assay kits used in HTS techniques, rising prevalence of a number of diseases, increasing pharmaceutical R&D, and increased government funding for life science research are driving the growth of this segments.

Based on technology, the label-free technology segment is expected to grow at the highest CAGR during the forecast period. The major advantage offered by label-free technology is that it can help in the study of varied cell types and targets. Label-free assays also provide simple methods for studying complex biological pathways. The label-free technology is set to reduce drug failure caused by toxicity. These factors are likely to boost the growth of this technology market.

On the basis of application, the target identification & validation segment accounted for the largest share of the global HTS market in 2017. The large share of this segment is attributed to the growing number of potential drug targets for screening.

Based on end user, the pharmaceutical and biotechnology companies accounted for the largest share of the global HTS market in 2017. Factors contributing to its largest share include the increasing use of HTS techniques by pharmaceutical and biotechnology companies for drug discovery applications along with the increasing pharmaceutical R&D expenditure.

Geographically, the global HTS market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2017, North America accounted for the largest share of the HTS market, followed by Europe and Asia Pacific. Factors such as the large spending on pharmaceutical R&D, growing adoption of HTS, availability of government funding, and the presence of major key players in the region are responsible for the large share of the North American HTS market.

The prominent players in the global HTS market are Agilent (US), Danaher (US), Thermo Fisher Scientific (US), PerkinElmer (US), Tecan (Switzerland), Axxam (Italy), Merck Group (Germany), Bio-Rad (US), Hamilton (US), Corning (US), BioTek (US), and Aurora Biomed (Canada).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 High-Throughput Screening: Market Overview
4.2 HTS Market: Developed vs Developing Countries (2018 vs 2023)
4.3 Geographic Snapshot: HTS Market (2017)
4.4 Geographic Mix: HTS Market
4.5 HTS Market, By Product & Services (2018 vs 2023)

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Growing Adoption of Open Innovation Models in Pharmaceutical and Biotechnology Companies
5.2.1.2 Government Funding and Venture Capital Investments
5.2.1.3 Increasing R&D Spending
5.2.1.4 Technological Advancements
5.2.2 Market Restraints
5.2.2.1 Capital-Intensive Nature of HTS
5.2.2.2 Complexities in the Field of Assay Development
5.2.3 Market Opportunities
5.2.3.1 Emerging Markets
5.2.3.2 Growing Research Activities in Toxicology and Stem Cells
5.2.4 Market Challenges
5.2.4.1 Dearth of Skilled Operators

6 Industry Insights
6.1 Introduction
6.2 Technological Trends
6.2.1 Label-Free Technology
6.2.2 Automation & Miniaturization
6.2.3 Microfluidics
6.3 HTS in Drug Discovery Process

7 High-Throughput Screening Market, By Product & Service
7.1 Introduction
7.2 Reagents & Assay Kits
7.3 Instruments
7.4 Consumables & Accessories
7.5 Software
7.6 Services

8 High-Throughput Screening Market, By Technology
8.1 Introduction
8.2 Cell-Based Assays
8.2.1 2D Cell Culture
8.2.2 3D Cell Culture
8.2.2.1 Scaffold-Based Technology
8.2.2.1.1 Hydrogels
8.2.2.1.1.1 Animal-Derived Hydrogels
8.2.2.1.1.1.1 Matrigel
8.2.2.1.1.1.2 Collagen
8.2.2.1.1.2 Synthetic Hydrogels
8.2.2.1.1.3 Alginate/Agarose
8.2.2.1.2 Inert Matrix/Solid Scaffolds
8.2.2.1.3 Micropatterned Surfaces
8.2.2.2 Scaffold-Free Technology
8.2.2.2.1 Microplates
8.2.2.2.2 Hanging-Drop Plates
8.2.2.2.3 Ultra-Low Binding Plates
8.2.2.2.4 Other Scaffold-Free Technologies
8.2.3 Perfusion Cell Culture
8.3 Lab-On-A-Chip
8.4 Ultra-High-Throughput Screening
8.5 Bioinformatics
8.6 Label-Free Technology

9 High-Throughput Screening Market, By Application
9.1 Introduction
9.2 Target Identification and Validation
9.3 Primary and Secondary Screening
9.4 Toxicology Assessment
9.5 Other Applications

10 High-Throughput Screening Market, By End User
10.1 Introduction
10.2 Pharmaceutical and Biotechnology Companies
10.3 Academic and Government Institutes
10.4 Contract Research Organizations (CRO)
10.5 Other End Users

11 High-Throughput Screening Market, By Region

12 Competitive Landscape
12.1 Introduction
12.2 Market Leadership Analysis
12.3 Competitive Scenario
12.3.1 Product Launches and Upgrades
12.3.2 Partnerships, Collaborations, and Agreements
12.3.3 Expansions
12.3.4 Acquisitions
12.3.5 Other Developments

13 Company Profiles

  • Agilent Technologies, Inc.
  • Aurora Biomed
  • Axxam S.P.A.
  • Bio-Rad Laboratories
  • Biotek Instruments
  • Corning Incorporated
  • Danaher Corporation
  • Hamilton Company
  • Merck Group
  • Perkinelmer, Inc.
  • Tecan Group
  • Thermo Fisher Scientific Inc.

For more information about this report visit https://ift.tt/2K52CIw

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery

Source link

No comments:

Pharmaceutical Validation Documentation Requirements

Pharmaceutical validation is a critical process that ensures that pharmaceutical products meet the desired quality standards and are safe fo...